Enzon Pharmaceuticals (ENZN) 10-K5 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2014	Feb. 23, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	ENZN
Entity Common Stock, Shares Outstanding		44,182,102
Entity Registrant Name	ENZON PHARMACEUTICALS INC
Entity Central Index Key	727510
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$45,195,458

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$34,562	$6,520
Other current assets	478	511
Assets held for sale	0	90
Total assets	35,040	7,121
Current liabilities:
Accounts payable	181	93
Accrued expenses and other current liabilities	458	1,215
Accrued dividends payable	4,417	0
Total current liabilities	5,056	1,308
Accrued rent liability	381	558
Total liabilities	5,437	1,866
Commitments and contingencies
Stockholdersâ€™ equity:
Preferred stock - $0.01 par value, authorized 3,000,000 shares; no shares issued and outstanding at December 31, 2014 and December 31, 2013	0	0
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 44,174,456 shares at December 31, 2014 and 44,085,870 shares at December 31, 2013	441	441
Additional paid-in capital	130,065	134,512
Accumulated deficit	-100,903	-129,698
Total stockholders' equity	29,603	5,255
Total liabilities and stockholders' equity	$35,040	$7,121

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	44,174,456	44,085,870
Common stock, shares outstanding	44,174,456	44,085,870

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Revenues:
Royalties	$31,038		$33,846
Miscellaneous income	135		647
Total revenues	31,173		34,493
Operating expenses:
Research and development	0		2,715
General and administrative	2,383		8,843
Restructuring charges	0		4,776
Total operating expenses	2,383		16,334
Operating income	28,790		18,159
Other income (expense):
Investment income, net	0		534
Interest expense	0		-2,124
Other, net, primarily gain on sale of assets in 2014	61		1,553
Income before income tax expense (benefit)	28,851		18,122
Income tax expense (benefit)	56		-28
Net income	28,795		18,150
Income per common share
Basic (in dollars per share)	$0.65		$0.41
Diluted (in dollars per share)	$0.65		$0.38
Weighted average number of shares
Basic (in shares)	44,125		43,782
Diluted (in shares)	44,245		51,045
Special cash dividend paid per common share (in dollars per share)	$0		$2.05
Net income	28,795		18,150
Other comprehensive income:
Unrealized gain on securities that arose during the year*	0	[1]	237	[1]
Reclassification adjustments*:
Gain on sale of securities	0	[1]	-320	[1]
Total other comprehensive (loss)	0		-83
Total comprehensive income	$28,795		$18,067

[1]	Information has not been tax-effected due to the establishment of a full allowance against any related net deferred tax asset.

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]
In Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2012	$77,468	$437	$224,796	$83	($147,848)
Balance (in shares) at Dec. 31, 2012		43,674
Net income	18,150	0	0	0	18,150
Other comprehensive loss	-83			-83
Stock-based compensation - withholding taxes	-484	4	-488	0	0
Stock-based compensation - withholding taxes (in shares)		409
Issuance of stock for employee stock purchase plan	12	0	12	0	0
Issuance of stock for employee stock purchase plan (in shares)		3
Common stock dividend	-89,808	0	-89,808	0	0
Balance at Dec. 31, 2013	5,255	441	134,512	0	-129,698
Balance at Dec. 31, 2013		44,086
Net income	28,795	0	0	0	28,795
Other comprehensive loss	0
Stock-based compensation - withholding taxes	-30	0	-30	0	0
Stock-based compensation - withholding taxes (in shares)		89
Common stock dividend	0	0	-4,417	0	0
Balance at Dec. 31, 2014	$29,603	$441	$130,065	$0	($100,903)
Balance at Dec. 31, 2014		44,175

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income	$28,795	$18,150
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation	0	232
Amortization and write-off of debt issuance costs	0	193
Impairment of property and equipment	0	0
Stock-based compensation and employee stock purchase plan discount	0	-205
Gain on sale of marketable securities	0	-320
Gain on sale of assets	-61	-1,554
Amortization of purchase premium on marketable securities	0	735
Changes in operating assets and liabilities:
Decrease in other current assets	33	1,334
Decrease in accounts payable	88	-683
Decrease in accrued expenses and other current liabilities	-934	-3,877
Increase in accrued dividends payable	4,417	0
Net cash provided by operating activities	32,338	14,005
Cash flows from investing activities:
Proceeds from sale of fixed assets	151	2,234
Proceeds from sales and maturities of marketable securities	0	118,894
Net cash provided by investing activities	151	121,128
Cash flows from financing activities:
Common stock dividend	-4,417	-89,808
Retirement of notes payable	0	-115,849
Proceeds from issuance of common stock	0	12
Withholding taxes - stock-based compensation	-30	-283
Redemptions from employee stock purchase plan, net	0	-33
Net cash used in financing activities	-4,447	-205,961
Net increase (decrease) in cash and cash equivalents	28,042	-70,828
Cash and cash equivalents at beginning of year	6,520	77,348
Cash and cash equivalents at end of year	$34,562	$6,520

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	-1	Description of Business

	Enzon Pharmaceuticals, Inc. (together with its subsidiaries, “Enzon” or the “Company”) receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron ^®, Sylatron ^®, Macugen ^® and CIMZIA ^®. The Company had previously received royalty revenues from licensing arrangement related to sales of Oncaspar and Adagen until the Company’s rights to receive royalties on sales of these products expired in 2014. In addition, the Company’s rights to receive royalties on sales of Macugen and CIMZIA expired in the U.S. and Great Britain in 2014. The primary source of the Company’s royalty revenues is sales of PegIntron, which is marketed by Merck & Co., Inc. (“Merck”). The Company currently has no clinical operations and limited corporate operations. Royalty revenues from sales of PegIntron accounted for approximately 79% and 87% of the Company’s total royalty revenues in 2014 and 2013, respectively.

	The Company was previously dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. In December 2012, the Company announced that the Company’s Board of Directors retained Lazard Frères & Co. LLC (“Lazard”) to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets or a sale of the Company and that the Company’s Board of Directors established a special committee to oversee the Company’s sale review process. In connection with the Company’s sale review process, the Company substantially suspended all clinical development activities with a goal of conserving capital and maximizing value returned to the Company’s stockholders. In April 2013, the Company announced that it had concluded a review of the sale or disposition of one or more corporate assets, or a sale of the Company. The review did not result in a definitive offer to acquire the Company or all or substantially all of the Company’s assets. In the same announcement, the Company also announced that its Board of Directors intends to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to stockholders.

	In April 2013, pursuant to the terms of an asset purchase agreement, the Company sold to Belrose Pharma, Inc. (“Belrose”), all right, title and interest to the Company’s Customized PEGylation platform and related assets. The assets included (i) intellectual property and know-how associated with the PEGylation platform, (ii) patents and know-how related to PEG- SN-38, (iii) patents and know-how associated with certain of the Company’s internal clinical programs and (iv) certain related supplies and equipment.

	In September 2013, the Company entered into a sublease agreement, which was amended and restated in November 2013, with Axcellerate Pharma, LLC (“Axcellerate”), pursuant to which the Company subleases to Axcellerate a portion of the Company’s premises consisting of approximately 30,000 rentable square feet of the building located at 20 Kingsbridge Road, Piscataway, New Jersey and a share of related parking areas. The term of the sublease commenced on November 14, 2013 and will expire on July 30, 2021. The monthly fixed rent payable by Axcellerate to us under the sublease is as follows: (i) in year one, $ 10,417, (ii) in year two, $ 15,625, (iii) in year three, $ 20,833, (iv) in year four, $ 26,042 and (v) in each of years five through eight, $ 35,000. The sublease also provides for Axcellerate to pay additional rent to cover its applicable share of real estate taxes, operating expenses, sewer and gas usage, water usage, electricity usage and certain other charges incurred by Axcellerate.

	In October 2013, the Company terminated its License and Collaboration Agreement with Santaris Pharma A/S (“Santaris”) whereby Enzon returned to Santaris the rights to molecules utilizing LNA technology including the mRNA antagonists targeting Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha), the Androgen Receptor (AR), HER3, and Beta-catenin.

	The Company has no intention of resuming any clinical development activities or acquiring new sources of royalty revenues.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	-2	Summary of Significant Accounting Policies

	Principles of Consolidation

	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.

	Use of Estimates

	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U. S. requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the carrying value of property and equipment, valuation of investments, legal and contractual contingencies, research and development expenses, stock-based compensation, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

	Financial Instruments and Fair Value

	The carrying values of cash, cash equivalents, marketable securities and other current assets, accounts payable and accrued expenses in the Company’s consolidated balance sheets approximated their fair values at December 31, 2014 and 2013 due to their short-term nature. As of December 31, 2014, the Company held no cash equivalents or marketable securities.

	Cash Equivalents

	The Company considers all highly liquid debt instruments purchased with original maturities of three months or less to be cash equivalents. As of December 31, 2014 and 2013, the Company held no cash equivalents.

	Revenue Recognition

	Royalty revenues from the Company’s agreements with third parties is recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee, which is typically during the quarter following the quarter in which the sales occurred. The Company does not participate in the selling or marketing of products for which it receives royalties. No provision for uncollectible accounts is established upon recognition of revenues.

	Contingent payments due under the asset purchase agreement for the sale of the Company’s former specialty pharmaceutical business are recognized as income when the milestone has been achieved and collection is assured. Such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process.

	The Company has discontinued all research and development activities.

	Income Taxes

	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.

	Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense.

	Concentrations of Risk

	At December 31, 2014 and 2013, the Company had invested none of its cash in financial instruments, nor does it anticipate holding such instruments in the future. In prior periods, holdings of financial instruments, were comprised, principally, of money market funds and debt securities.

	Stock-Based Compensation Plans

	The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned.

	The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at date of grant or modification and vesting, including the likelihood of achieving performance goals. Furthermore, the application of the Black-Scholes valuation model employs weighted average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk free interest rate, and dividends, if any to determine fair value. Expected volatility is based on historical volatility of the Company’s common stock; the expected term until exercise represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.

	Cash Flow Information

	Cash payments for interest on the Company’s 4% convertible notes were approximately $2.3 million for the year ended December 31, 2013. There were approximately $55,500 and $186,000 (for which a refund request was submitted) of income tax payments made for the years ended December 31, 2014 and 2013, respectively.

Recently_Adopted_Accounting_Pr

Recently Adopted Accounting Pronouncements	12 Months Ended
	Dec. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Description of New Accounting Pronouncements Not yet Adopted [Text Block]		-3	Recently Adopted Accounting Pronouncements

	In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The update changes the requirements for reporting discontinued operations in Subtopic 205-20. A discontinued operation may include a component of an entity or a group of components of an entity, or a business. A disposal of a component of an entity or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business or a major equity method investment. Additionally, the update requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income and expenses of discontinued operations. This update is effective prospectively for reporting periods beginning after December 15, 2014 and early adoption is permitted. The Company is currently evaluating the impact adoption will have on its financial statements.

	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) . The core principle of this ASU is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU provides for one of two methods of transition: retrospective application to each prior period presented; or, recognition of the cumulative effect of retrospective application of the new standard in the period of initial application. This ASU is effective for fiscal years and interim periods beginning after December 15, 2016 and early application is not permitted. Management currently believes the adoption this ASU will not have a material impact on the Company’s operating results, financial position or cash flows.

	In June 2014, the FASB issued ASU No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period . The issue is the result of a consensus of the FASB Emerging Issues Task Force (EITF). The amendments in this ASU require that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015 and can be either applied prospectively or retrospectively. Earlier adoption is permitted. Management currently believes the adoption this ASU will not have a material impact on the Company’s operating results, financial position or cash flows.

Marketable_Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	-4	Marketable Securities

	At December 31, 2014 and 2013, the Company held no marketable securities.

	For the year ended December 31, 2013, the Company realized a net gain from the sale of marketable securities of $0.3 million. The Company includes realized gains and losses, if any, in the accompanying Consolidated Statements of Income and Comprehensive Income, in Investment Income.

Accrued_Expenses_and_Other

Accrued Expenses and Other	12 Months Ended
Accrued Expenses and Other	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]		-5	Accrued Expenses and Other

	Accrued expenses and other current liabilities consist of the following as of December 31, 2014 and 2013 (in thousands):

			December 31,		December 31,
			2014		2013
	Compensation		$	5	$	85
	Severance benefits			-		332
	Professional and consulting fees			88		150
	Legal			-		160
	Rent			171		239
	Other			194		249
			$	458	$	1,215

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]		-6	Stockholders’ Equity

	Preferred Stock

	The Company has authorized 3,000,000 shares of preferred stock in one or more series of which 600,000 had previously been designated as Series B in connection with the Rights Plan, which expired on May 16, 2012.

	Common Stock

	As of December 31, 2014, the Company reserved 7,097,697 shares of its common stock for the non-qualified and incentive stock plans.

	Share Repurchase Programs

	On December 21, 2010, the Company announced that its Board of Directors had authorized a share repurchase program, under which the Company is authorized to repurchase up to $ 200.0 million of the Company’s outstanding common stock. During the first quarter of 2012, the Company announced its plans to resume repurchasing its outstanding common stock under this program. No shares were repurchased during the years ended December 31, 2014 and 2013. Since the inception of this program, the cumulative number of shares repurchased and retired through December 31, 2014 amounted to 16,174,578 shares at a total cost of $153.4 million, or an average cost of approximately $ 9.48 per share. Since the third quarter of 2012, the Company has suspended repurchases under the share repurchase program and does not currently intend to resume repurchases under the share repurchase program.

Miscellaneous_Income

Miscellaneous Income	12 Months Ended
	Dec. 31, 2014
Miscellaneous Income [Abstract]
Miscellaneous Income [Text Block]	-9	Miscellaneous Income

	Sublease income in 2014 and 2013, aggregated approximately $135,000 and $87,000, respectively, relating, primarily, to Axcellerate Pharma, LLC, the Company's subtenant at its Piscataway, New Jersey facility. (See Note 20, Leases.)

Cash_Dividend

Cash Dividend	12 Months Ended
	Dec. 31, 2014
Dividends, Cash [Abstract]
Cash Dividend [Text Block]		-10	Cash Dividend

	On December 5, 2014, the Company’s Board of Directors declared a special cash dividend of $.10 per share of common stock. This special cash dividend was paid on January 28, 2015 to stockholders of record as of January 12, 2015.

	On April 23, 2013, the Company’s Board of Directors declared a special cash dividend of $ 1.60 per share of common stock. This special cash dividend was paid on June 4, 2013 to stockholders of record as of May 7, 2013.

	On December 5, 2013, the Company’s Board of Directors declared a special cash dividend of $ 0.45 per share of common stock. This special cash dividend was paid on December 23, 2013 to stockholders of record as of December 16, 2013.

Income_Per_Common_Share

Income Per Common Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]		-11	Income Per Common Share

	Basic income per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during the period. Restricted stock awards and restricted stock units (collectively, nonvested shares) are not considered to be outstanding shares until the service or performance vesting period has been completed.

	The diluted income per share calculation would normally involve adjusting both the denominator and numerator as described here if the effect is dilutive. The denominator would include both the weighted average number of shares of common stock outstanding and common stock equivalents. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method and shares issuable under the employee stock purchase plan (ESPP) interest would not have been incurred if the notes were converted into common stock.

	In a period in which a loss from continuing operations is reported, all computations of diluted per-share amounts for that period must be made exclusive of potential dilutive shares and the add-back of interest.

	For the years ended December 31, 2014 and 2013, stock options to purchase approximately 0 and 22,000 shares, respectively, of common stock were excluded from the calculation of diluted earnings per share as their inclusion would be anti-dilutive.

Restructurings

Restructurings	12 Months Ended
Restructurings	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]		-12	Restructurings

	The Company incurred charges aggregating approximately $4.8 million in connection with its restructuring programs during the year ended December 31, 2013. No such charges were incurred in 2014.

	Employee Separation Benefits

	No employee separation costs were incurred in 2014, as all such costs were previously accrued. During 2013, the Company incurred separation costs of $4.0 million relating to terminating employees. During 2013, prior accruals for certain benefits provided to existing employees were adjusted downward by $32,000, based on accrual utilization.

	The following table summarizes the changes in the Company’s accrued restructuring liabilities for the year ended December 31, 2014 and 2013 (in thousands):

			2014		2013

	Balance, beginning of year		$	905	$	777
	Payments made			-555		-4,648
	Adjustments			-82		-167
	Restructuring accruals			-		4,943

	Balance, end of year		$	268	$	905

Stock_Options

Stock Options	12 Months Ended
Stock Options	Dec. 31, 2014
Stock Options Abstract [Abstract]
Stock Options Disclosure Text Block [Text Block]		-13	Stock Options

	Through the Compensation Committee of the Company’s Board of Directors, the Company administers the 2011 Stock Option and Incentive Plan, which provides incentive and non-qualified stock option benefits for employees, officers, directors and independent contractors providing services to Enzon and its subsidiaries. The 2011 Stock Option and Incentive Plan was adopted by the Board of Directors in March 2011 and approved by the stockholders in May 2011. Prior to this, the Company administered the 2001 Incentive Stock Plan, which was adopted by the Company’s Board of Directors in October 2001 and approved by the stockholders in December 2001. Options granted to employees generally vest over four years from date of grant and options granted to directors vest after one year. The exercise price of the options granted must be at least 100 percent of the fair value of the Company’s common stock at the time the options are granted. Options may be exercised for a period of up to ten years from the grant date. As of December 31, 2014, the 2011 plan authorized equity-based awards for 5 million common shares of which about 4.4 million shares remain available for grant. Option grants remain outstanding from previous awards under the 2001 Incentive Stock Plan and an earlier 1987 Non-Qualified Stock Option Plan; however, there will be no further grants made pursuant to those plans.

	2013 Outside Director Compensation Plan

	In January 2013, the Governance and Nominating Committee reviewed director compensation in view of changes in the size and direction of the Company and trends in director compensation at peer group companies. In January 2013, the Board of Directors adopted the 2013 Outside Director Compensation Plan, which remained in effect until the Amended and Restated 2013 Outside Director Compensation Plan (described below) became effective on July 1, 2013. Under the 2013 Outside Director Compensation Plan, each non-employee director receives an annual grant of stock options on the first trading day of the calendar year with a Black-Scholes value of $ 25,000 and an exercise price equal to the closing price of the Company’s Common Stock on the date of grant (the “2013 Plan Annual Option Grant”) and an annual grant of restricted stock units settled in shares of Common Stock on the first trading day after June 30 of each calendar year with a value of $ 50 ,000 (the “2013 Plan Annual Restricted Stock Grant”). These grants are made under the Company’s equity compensation plans. The 2013 Plan Annual Option Grant vests in one tranche on the first anniversary of the date of grant if the recipient director remains on the Company’s Board of Directors on that date. Once vested, options granted pursuant to the 2013 Plan Annual Option Grant expire on the 10th anniversary of the date of grant. The number of shares issued in the 2013 Plan Annual Restricted Stock Grant will be equal to $ 50,000 divided by the closing price of the Company’s Common Stock on the date of grant. The shares covered by the 2013 Plan Annual Restricted Stock Grant vest in three equal tranches on each of the first three anniversaries of the date of grant if the recipient director remains on the Company’s Board of Directors on each such date. Upon the election of a new non-employee director to the Board of Directors , such newly elected director will receive a grant of stock options with a Black-Scholes value of $ 25 ,000 (the exercise price of which will be equal to the closing price of our Common Stock on the date of grant) and a grant of restricted stock units settled in shares of Common Stock with a value of $ 50,000 (the number of shares covered by such grant being equal to $ 50,000 divided by the closing price of our Common Stock on the date of grant) (the “2013 Plan Welcome Grant”). The options and restricted stock units included in the 2013 Plan Welcome Grant vest in three equal tranches on each of the first three anniversaries of the date of grant, if the recipient director remains on the Board of Directors on each such date. For the Chairperson of the Board of Directors, if such Chairperson is not an employee of the Company, the value of the options and restricted stock units covered by the 2013 Plan Annual Option Grant, Annual Restricted Stock Grant and 2013 Plan Welcome Grant are twice the amounts mentioned above. For the Vice-Chairperson of the Board of Directors, if such Vice-Chairperson is not an employee of the Company, the value of the options and restricted stock units covered by the 2013 Plan Annual Option Grant, 2013 Plan Annual Restricted Stock Grant and 2013 Plan Welcome Grant are 1.75 times the amounts mentioned above. In addition, under the 2013 Outside Director Compensation Plan, each non-employee director receives an annual cash retainer of $ 30,000. Non-employee directors also receive an additional annual cash retainer of $ 18,000 for service as chair of the Finance and Audit Committee and $ 8,000 for service as chair of any other committee. Non-employee directors receive an additional annual cash retainer of $ 8,000 for service as members of the Audit and Finance Committee, an annual cash retainer of $ 4,000 for each other committee on which they serve but do not chair.

	Amended and Restated 2013 Outside Director Compensation Plan

	In June 2013, the Governance and Nominating Committee further reviewed director compensation in view of changes in the size and direction of our company. The Governance and Nominating Committee recommended further changes to eliminate equity grants and reduce cash compensation to non-employee directors. Based upon these recommendations, in June 2013, the Board adopted the Amended and Restated 2013 Outside Director Compensation Plan, which became effective on July 1, 2013. Under the Amended and Restated 2013 Outside Director Compensation Plan, each non-employee director (i) receives an annual cash retainer of $ 30,000, (ii) for service as chair of the Finance and Audit Committee receives an additional annual cash retainer of $ 10,000 and (iii) for service as a member of the Finance and Audit Committee receives an additional annual cash retainer of $ 5,000. These annual cash retainers are payable quarterly at the end of each quarter, beginning with the third quarter of the fiscal year ending December 31, 2013.

	Directors who are employees of the Company do not receive compensation for their service on the Board.

	In March 2011, the Company’s Board of Directors adopted a new compensation plan for non-employee directors, effective April 1, 2011. Under the 2011 Outside Director Compensation Plan, each non-employee director receives an annual grant of stock options (Annual Option Grant) on the first trading day of the calendar year with a Black-Scholes value of $ 25,000 and an exercise price equal to the closing price of the Company’s common stock on the date of grant. The Annual Option Grant vests in one tranche on the first anniversary, provided that the recipient director remains on the Board, and expires on the tenth anniversary of the date of grant. In addition, upon the election of a new non-employee director to the Board, such newly elected director receives a Welcome Grant of stock options with a Black-Scholes value of $ 25,000 and an exercise price equal to the closing price of the Company’s common stock on the date of grant. The Welcome Grant vests in three equal tranches on each of the first three anniversaries, provided that the recipient director remains on the Board, and expires on the tenth anniversary of the date of grant. Furthermore, for a non-employee Chairperson of the Board, the value of options covered by the Annual Option Grant and the Welcome Grant shall be twice the amounts mentioned above. For a non-employee Vice-Chairperson of the Board of Directors, the value of options covered by the Annual Option Grant and the Welcome Grant shall be one and a half times the amounts mentioned above. Options granted in accordance with the 2011 Outside Director Compensation Plan will be made under the 2011 Stock Option and Incentive Plan.

	Prior to April 1, 2011, under the 2007 Outside Director Compensation Plan, each non-employee director received an annual grant of stock options (Annual Option Grant) on the first trading day of the calendar year with a Black-Scholes value of $ 75,000 and an exercise price equal to the closing price of the Company’s common stock on the date of grant. The Annual Option Grant vested in one tranche on the first anniversary, provided that the recipient director remained on the Board, and expired on the tenth anniversary of the date of grant. In addition, upon the election of a new non-employee director, such newly elected director received a Welcome Grant of stock options with a Black-Scholes value of $ 75,000 and an exercise price equal to the closing price of the Company’s common stock on the date of grant. The Welcome Grant vested in three equal tranches on each of the first three anniversaries, provided that the recipient director remained on the Board of Directors and expired on the tenth anniversary of the date of grant. Furthermore, for a non-employee Chairperson of the Board of Directors, the value of options covered by the Annual Option Grant and Welcome Grant were twice the amounts mentioned above. Options granted in accordance with the 2007 Outside Director Compensation Plan were made under the 2001 Incentive Stock Plan.

	On December 5, 2014, the Company’s Board of Directors declared a special cash dividend of $ .10 per share of common stock. This special cash dividend was paid on January 28, 2015 to stockholders of record as of January 12, 2015. In connection with this special cash dividend, the Compensation Committee of the Company’s Board of Directors approved equitable adjustments to the Company’s outstanding stock options and restricted stock units.

	On April 23, 2013, the Company’s Board of Directors declared a special cash dividend of $ 1.60 per share of common stock. This special cash dividend was paid on June 4, 2013 to stockholders of record as of May 7, 2013. On December 5, 2013, the Company’s Board of Directors declared a special cash dividend of $ 0.45 per share of common stock. This special cash dividend was paid on December 23, 2013 to stockholders of record as of December 16, 2013. In connection with these two special cash dividends, the Compensation Committee of the Company’s Board of Directors approved equitable adjustments to the Company’s outstanding stock options and restricted stock units. The compensation cost recognized during 2013 relating to these modifications was approximately $4,000.

	The following is a summary of the activity in the Company’s outstanding Stock Option Plans, which include the 2011 Stock Option and Incentive Plan, the 2001 Incentive Stock Plan, and the 1987 Non-Qualified Stock Option Plan (options in thousands):

					Weighted			Weighted
					Average			Average
					Exercise			Remaining		Aggregate
					Price Per			Contractual		Intrinsic
			Options		Option			Term (years)		Value ($000)

	Outstanding at January 1, 2014			2,125	$	6.9
	Granted at exercise prices which equaled the fair value on the date of grant			-	$	-
	Exercised			-	$	-

					$	-
	Expired and Forfeited			-1,606	$	7.64

	Outstanding at December 31, 2014			519	$	4.08			2.53	$	-

	Vested and expected to vest at December 31, 2014			519	$	4.08			2.53	$	-

	Exercisable at December 31, 2014			470	$	4.51			2.26	$	-

	As of December 31, 2014, there was no unrecognized compensation cost related to unvested options that the Company expects to recognize.

	The weighted-average grant-date fair value of options granted during the years ended December 31, 2014 and 2013 was $ 0 and $ 1.24, respectively. The total intrinsic value of options exercised during each of the years ended December 31, 2014 and 2013 was $ 0.

	In the years ended December 31, 2014 and 2013, the Company recorded stock-based compensation of $ 0 and $ 0.1 million, respectively, related to stock options. The Company did not realize a net tax benefit related to stock-based compensation expense. The Company’s policy is to use newly issued shares to satisfy the exercise of stock options.

	The breakdown of stock-based compensation expense related to stock options by major line caption in the statements of income is shown below (in thousands):

			Year Ended December 31,
			2014		2013
	Research and development		$	-	$	5
	General and administrative			-		75
			$	-	$	80

	The Company received no cash from exercises of stock options in either of the years ended for the years ended December 31, 2014 and 2013.

	The weighted average assumptions used in the Black-Scholes option-pricing model for expected volatility, expected term until exercise and risk-free interest rate are shown in the table below. Expected volatility is based on historical volatility of the Company’s common stock. The expected term of options is estimated based on the Company’s historical exercise pattern. The risk-free interest rate is based on U.S. Treasury yields for securities in effect at the time of grant with terms approximating the expected term until exercise of the option. No dividend payments were factored into the valuations. Forfeiture rates, used for determining the amount of compensation cost to be recognized over the service period, are estimated based on stratified historical data.

			Year Ended December 31,
			2013
	Expected volatility						34.3	%
Expected term (in years)						4	%
Risk-free interest rate						0.8	%

Restricted_Stock_Awards_and_Re

Restricted Stock Awards and Restricted Stock Units (Nonvested Shares)	12 Months Ended
	Dec. 31, 2014
Restricted Stock Awards And Restricted Stock Units [Abstract]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Text Block]	(14) Restricted Stock Awards and Restricted Stock Units (Nonvested Shares)

	The 2011 Stock Option and Incentive Plan and, prior to that, the 2001 Incentive Stock Plan provide for the issuance of restricted stock awards and restricted stock units (collectively, nonvested shares) to employees, officers and directors. These awards are issued by the Company effective as of the grant date, in the case of restricted stock awards, or upon the vesting date, in the case of a restricted stock unit. The recipient pays no cash to receive the shares, other than the $ 0.01 par value per share in some cases. These awards have vesting periods of three to five years when based solely on service. Certain awards have performance goals, which, if met, result in accelerated vesting that could be shorter than three years. If the performance goals are not met, the awards continue to vest over time. All nonvested shares are valued at fair value. The market price of the Company’s stock at grant date is factored by an expected vesting period forfeiture rate based on stratified historical data related to the assumed vesting period. This amount is then amortized over the vesting period on a straight-line basis for those awards that vest based solely on service. For awards subject to performance-based accelerated vesting, the Company monitors progress against performance goals and accelerates the compensation expense as appropriate.

	Under the 2011 Outside Director Compensation Plan, each non-employee director receives an annual grant of restricted stock units (Annual Restricted Stock Grant) settled in shares of common stock on the first trading day after June 30 of each calendar year with a value of $ 75,000. The Annual Restricted Stock Grant vests in three equal tranches on each of the first three anniversaries of the date of grant, provided that the recipient director remains on the Board. In addition, upon the election of a new non-employee director to the Board, such newly elected director receives a Welcome Grant of restricted stock units settled in shares of common stock with a value of $ 100,000. The Welcome Grant vests in three equal tranches on each of the first three anniversaries of the date of grant, provided that the recipient director remains on the Board. Furthermore, for a non-employee Chairperson of the Board, the value of restricted stock units covered by the Annual Restricted Stock Grant and the Welcome Grant shall be twice the amounts mentioned above. For a non-employee Vice-Chairperson of the Board, the value of options covered by the Annual Restricted Stock Grant and the Welcome Grant shall be one and a half times the amounts mentioned above. Restricted stock units granted in accordance with the 2011 Outside Director Compensation Plan will be made under the 2011 Stock Option and Incentive Plan.

	Prior to April 1, 2011, under the 2007 Outside Director Compensation Plan, each non-employee director received an annual grant of restricted stock (Annual Restricted Stock Grant) settled in shares of common stock on the first trading day after June 30 of each calendar year with a value of $ 75,000. The Annual Restricted Stock Grant vested in three equal tranches on each of the first three anniversaries of the date of grant, provided that the recipient director remained on the Board. In addition, upon the election of a new non-employee director, such newly elected director received a Welcome Grant of restricted stock with a value of $ 75,000. The Welcome Grant vested in three equal tranches on each of the first three anniversaries of the date of grant, provided that the recipient director remained on the Board. Furthermore, for a non-employee Chairperson of the Board, the value of restricted stock covered by the Annual Restricted Stock Grant and Welcome Grant were twice the amounts mentioned above. Restricted stock units granted in accordance with the 2007 Outside Director Compensation Plan were made under the 2001 Incentive Stock Plan.

	In connection with the Company’s special cash dividends of $ 1.60 per share of common stock paid on June 4, 2013 and $ 0.45 per share of common stock paid on December 23, 2013 (See Note 11) the Company’s Board of Directors approved equitable adjustments to the Company’s outstanding stock options and restricted stock units.

	A summary of nonvested shares as of December 31, 2014 and changes during the year ended December 31, 2014 is provided below (shares in thousands):

				Weighted
				Average
		Number of		Grant Date
		Nonvested		Fair Value
		Shares		Per Share
	Nonvested at January 1, 2014		166	$	8.13
	Granted		-	$	-
	Vested		-121	$	8.77
	Forfeited		-	$	-
	Adjustment pursuant to special dividend		-	$	-
	Nonvested at December 31, 2014		45	$	6.33

	The total grant-date fair value of nonvested shares that vested during the year ended December 31, 2014 was $ .2 million.

	As of December 31, 2014 there was no unrecognized compensation cost related to nonvested shares that the Company expects to be recognized.

	In 2013, the Company reversed stock-based compensation costs based on revised estimates. Accordingly, for the years ended December 31, 2014 and 2013, the Company recorded stock-based compensation expense of $0.01 million and $(0.3) million, respectively, related to nonvested share awards, which is included in the Company’s net income for each respective period.

	Shares were withheld to pay $ 0.03 million of taxes on behalf of the employees and resulted in a net incremental charge to additional paid in capital of $ 0.03 million in 2014. Shares were withheld to pay $ 0.3 million of taxes on behalf of the employees and resulted in a net incremental charge to additional paid in capital of $ 0.5 million in 2013. There has been no tax benefit realized to date related to tax deductions for nonvested shares.

	The breakdown of stock-based compensation expense related to nonvested shares by major line caption in the statements of income is shown below (in thousands):

		Year Ended December 31,
		2014		2013

	Research and development	$	-	$	210

	General and administrative		-		-491

		$	-	$	-281

Employee_Stock_Purchase_Plan

Employee Stock Purchase Plan

12 Months Ended

Dec. 31, 2014

Employee Stock Purchase Plan [Abstract]

Employee Stock Purchase Plan [Text Block]

-15

Employee Stock Purchase Plan

The 2007 Employee Stock Purchase Plan (ESPP) permits eligible employees to purchase common stock through payroll deductions which may not exceed 15 percent of the employee’s compensation, as defined, at a price equal to 85 percent of the fair market value of the shares at the beginning of the offering period (grant date) or at the end of the offering period (purchase date), whichever is lower. There are two six-month offering periods in each plan fiscal year, beginning April 1 and October 1. The ESPP is intended to qualify under section 423 of the Internal Revenue Code. Individual participant purchases within a given calendar year are limited to $ 25,000 ($ 21,250 based on the 15 -percent discount) and no more than 2,500 shares on any single purchase date. An additional one million shares were reserved for issuance under the plan. All benefit-eligible employees of the Company may participate in the ESPP other than those who own shares or hold options or nonvested shares representing a combined 5 percent or more of the voting power of the Company’s outstanding stock. The ESPP was terminated on April 1, 2013.

The fair value of shares to be issued under the ESPP is estimated at the grant date and is comprised of two components: the 15 percent discount to fair value of the shares at grant date and the value of the option granted to participants pursuant to which they may purchase shares at the lower of either the grant date or the purchase date fair value. The option component is valued using the Black-Scholes option pricing model.

The initial assumptions used in the valuation for each offering period, April 1 and October 1, are reflected in the following table (no dividends were assumed):

2014

2013

October

April

October

April

Expected volatility

N/A

26.34

Expected term (in years)

N/A

0.5

Risk-free interest rate

N/A

0.15

Increases in individual withholding rates within the offering period could have the effect of establishing a new measurement date for that individual’s future contributions. In 2013, in connection with the termination of the ESPP, the Company recorded income of approximately $ 4,000 as the reversal of previously accrued expense. There was no compensation expense recognized for the ESPP in 2014 and 2013. Amounts withheld from participants are classified as cash from financing activities in the cash flow statement and as a liability in the balance sheet until such time as shares are purchased. There were no stock purchases under the ESPP during the year ended December 31, 2014 and 2013.

There was no cash received from ESPP for the years ended December 31, 2014. In 2013, in connection with the termination of the ESPP, the Company refunded $ 14,000 .

The categorization of stock-based compensation expense by major line caption in the statement of operations is shown below (in thousands).

Year Ended December 31,

2014

2013

Research and development

-3

General and administrative

-1

-4

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]		-16	Income Taxes

	The components of the income tax provision (benefit) are summarized as follows (in thousands):

			Year Ended December 31,
			2014		2013
	Current:
	Federal		$	-	$	-30
	State and foreign			56		2
	Total current			56		-28
	Deferred: Federal and State			-		-

	Income tax provision (benefit)		$	56	$	-28

	The following table represents reconciliation between the reported income taxes and the income taxes that would be computed by applying the federal statutory rate ( 35 %) to income from continuing operations before taxes (in thousands):

			Year Ended December 31,
			2014		2013
	Income tax expense computed at federal statutory rate		$	10,097	$	6,313
	Nondeductible expenses			-		183
	Add (deduct) effect of:
	Tax on earnings of foreign subsidiary			56		-
	State income taxes, net of federal tax			-		2

	Increase (decrease) in beginning of period valuation allowance			-10,097		-6,526

	Income tax provision (benefit)		$	56	$	-28

	No federal income tax expense was incurred in relation to normal operating results due to the utilization of deferred tax assets to offset taxes that would otherwise accrue to operating income.

	As of December 31, 2014 and 2013, the tax effects of temporary differences that give rise to the deferred tax assets and deferred tax liabilities are as follows (in thousands):

			December 31,		December 31,
			2014		2013
	Deferred tax assets:
	Federal and state net operating loss carryforward		$	45,221	$	56,198
	Research and development credits carryforward			19,911		25,379
	Basis difference in fixed Assets			2,915		3,526
	Capital loss carryforwards			3,647		3,663
	Share-based compensation			2,518		2,518
	Federal alternative minimum tax credits			1,530		1,530
	Writedown of carrying value of investment			-		-
	Accrued compensation			43		84
	Other			1,109		1,537
	Total gross deferred tax assets			76,894		94,435
	Less valuation allowance			-76,894		94,935
	Net deferred tax assets		$	-	$	-

	A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2014, the Company had federal net operating loss carryforwards of approximately $117.4 million that expire in the years 2020 through 2031 and New Jersey state net operating loss carryforwards of approximately $45.7 million that expire in the years 2029 through 2031. Moreover, the Company has federal and New Jersey capital loss carryforwards of approximately $8.9 million that expire in 2016 through 2019. The Company also has federal research and development tax credit carryforwards of approximately $16.6 million for tax reporting purposes that expire in the years 2017 through 2031. In addition, the Company has $3.3 million of state research and development tax credit carryforwards that expire in the years 2015 through 2026. The Company’s ability to use the net operating loss and research and development tax credit carryforwards is subject to certain limitations due to ownership changes, as defined by rules pursuant to Section 382 of the Internal Revenue Code of 1986, as amended.

	As of December 31, 2014, management believes that it is more likely than not that the net deferred tax assets will not be realized, based on assumptions regarding future operations, consideration of tax strategies and the reversal of deferred tax liabilities. Inasmuch as the Company has had net income only in each of the last two years and future earnings are not reasonably assured, management of the Company believes that a valuation allowance remains appropriate at this time. The valuation allowance will be reviewed and evaluated on a quarterly and annual basis. As of December 31, 2014 and 2013, the Company had deferred tax assets of $ 76.9 million and $ 94.4 million, respectively. The Company has maintained a valuation allowance of $ 76.9 million and $ 94.4 million at December 31, 2014 and 2013, respectively.

	The Company files income tax returns in the U.S. federal jurisdiction, various state jurisdictions and Canada. In January 2015, the Company concluded an examination by the U.S. Internal Revenue Service, in connection with the tax years 2010 through 2011. The result of such examination was the reduction of federal net operating loss carryforwards aggregating approximately $1.8 million. State income tax returns for the states of New Jersey and Indiana are generally subject to examination for a period of 3-4 years after filing of the respective returns. Income tax returns for Canada are generally subject to examination for a period of 3-5 years after filing of the respective return. For federal purposes, tax years 2011 through 2013 are open and for New Jersey purposes, tax years 2011 through 2013 are currently open for examination. No tax return in any jurisdiction is currently under audit.

Significant_Agreements

Significant Agreements	12 Months Ended
	Dec. 31, 2014
Significant Agreements [Abstract]
Significant Agreements Disclosure [Text Block]		-17	Significant Agreements

	Merck Agreement

	As a result of a November 1990 agreement, the Company’s PEGylation technology was used to develop an improved version of the product INTRON A, PegIntron. Merck is responsible for marketing and manufacturing PegIntron on an exclusive worldwide basis and the Company receives royalties on worldwide sales of PegIntron for all indications. The Company has no involvement in the selling or marketing of PegIntron. Merck’s obligation to pay the Company royalties on sales of PegIntron terminates, on a country-by-country basis, upon the later of the date on which the last patent to contain a claim covering PegIntron expires in the country or 15 years after the first commercial sale of PegIntron in such country. Currently, expirations are expected to occur in 2016 in the U.S., 2018 in Europe and 2019 in Japan. The royalty percentage to which the Company is entitled will be lower in any country where a PEGylated alpha-interferon product is being marketed by a third party in competition with PegIntron where such third party is not Hoffmann-La Roche. Either party may terminate the agreement upon a material breach of the agreement by the other party that is not cured within 60 days of written notice from the non-breaching party or upon declaration of bankruptcy by the other party. During the quarter ended September 30, 2007, the Company sold a 25 -percent interest in future royalties payable to it by Merck on net sales of PegIntron occurring after June 30, 2007.

	Sigma-Tau Group

	The Company sold its former specialty pharmaceutical business to Klee Pharmaceuticals Inc. (now known as Sigma-Tau PharmaSource, Inc.), Defiante Farmacêutica, S.A and sigma-tau Finanziaria S.p.A. (collectively, the Sigma-Tau Group) in January 2010. In addition to the initial sale of assets which has been reflected in the Company’s financial statements for the year ended December 31, 2010, the sale agreement provides for certain potential future payments due to Enzon of up to $ 27.0 million contingent upon the achievement of the following regulatory approval-related milestones:

		·	$ 5.0 million due for accelerated European Medicines Agency (EMA, formerly known as EMEA) approval, in addition to the amount due for non-accelerated EMA approval, for SC Oncaspar;

		·	$ 5.0 million due for FDA approval for SS Oncaspar;

		·	$ 7.0 million due for FDA approval for SC Oncaspar; and

		·	$ 10.0 million due for non-accelerated EMA approval for SC Oncaspar.

	In addition, the sale agreement provides for royalties potentially due to Enzon, beginning in 2010, of 5 to 10 percent on incremental net sales (net sales above a 2009 baseline amount) through 2014 of the Company’s former four marketed specialty pharmaceutical products sold to Sigma-Tau Group.

	The Company has no direct involvement in, and no obligations to perform services or activities related to, obtaining the above regulatory approvals or achieving commercial sales for the four marketed products. The Company recognizes revenue only upon notification from Sigma-Tau Group that the conditions necessitating payment of the milestone or royalty were achieved. In the case of the royalty, revenue is recognized in the quarter following the quarter in which the sales occurred.

	During the first quarter of 2011, the Company earned the $ 5.0 million due for FDA approval for SS Oncaspar. Approximately $ 0.5 million of royalty revenues were recognized in 2011 pursuant to this provision of the sale agreement. No additional revenue from this source was received, subsequently. There can be no assurance that the Company will receive any of the remaining $ 17.0 million of milestone payments or any future royalty revenues beyond those recognized to date. Our rights to receive royalties on sales of Oncaspar expired in 2014.

	Santaris Pharma A/S License Agreement

	In July 2006, the Company entered into a license agreement with Santaris Pharma A/S (Santaris) pursuant to which the Company obtained exclusive rights worldwide, other than in Europe, to develop and commercialize RNA antagonists directed against the HIF-1α and Survivin mRNA (which was returned to Santaris in late 2012), as well as RNA antagonists directed against six additional gene targets selected by the Company. Since inception of the agreement, initial acquisition of in-process research and development and milestone payments have been made totaling $ 34.0 million. This agreement provided that any one of the compounds licensed by us from Santaris could be returned to Santaris if the findings of our preclinical or clinical work do not support our continued investment. By September 2013, we returned all of the targets to Santaris.

	Nektar Agreement

	In January 2002, the Company entered into a PEGylation technology licensing agreement with Nektar under which the Company granted Nektar the right to grant sub-licenses for a portion of its patents related to its PEGylation technology to third-parties. Nektar had the right to sub-license Enzon’s patents that were defined in the January 2002 agreement and the Company will receive a royalty or a share of Nektar’s profits for any products that utilize the Company’s patented PEGylation technology. The Company’s receipt of royalties related to Nektar licenses ended in 2014. After the expiration of our sublicensed patents, we may be entitled to lesser immunity fees on a country-by-country and product-by- product basis for up to twelve years from the date of first sale of these drugs. Effective in January 2007, Nektar’s right to grant additional sublicenses was limited to a certain class of the Company’s PEGylation technology. Existing sublicenses granted by Nektar prior to January 2007 were unaffected.

	In March 2014, the Company entered into a novation agreement with Zhejiang Hisun Pharmaceutical Co., Ltd. ("Hisun") and Belrose (the “Novation Agreement”), pursuant to which the parties confirmed the novation of our Collaboration Agreement with Hisun to Belrose. As a consequence of entering into the Novation Agreement, the Company received a gross amount of $550,000 from Hisun, the amount of a receivable previously written off, and paid $249,565 to Belrose. The recording of these transactions resulted in a net reduction of general and administrative expense of $300,435 during the first quarter of 2014.

	On July 16, 2014, Belrose provided written notice to Hisun asserting multiple breaches by Hisun of the Collaboration Agreement including failure to pay $450,000 of milestone payments. Belrose provided Hisun up to 60 days to cure the breaches. On September 16, Belrose notified Hisun and the Company that it was terminating the Collaboration Agreement and demanded the return of material related to PEG-SN38 and a royalty-free right to any Hisun patents related to PEG-SN38. Hisun responded on September 16 that they rejected Belrose’s assertion that Hisun had committed multiple breaches and requested that Belrose continue its performance of technology transfer under the Collaboration Agreement.

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]		-18	Commitments and Contingent Liabilities

	The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2014
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]		-19	Leases

	On November 13, 2013, the Company and Axcellerate Pharma, LLC (“Axcellerate”) entered into an amendment and restatement of the previously announced Agreement of Sublease, dated as of September 26, 2013, between the Company and Axcellerate (the “Amended and Restated Sublease Agreement”) to incorporate certain amendments requested by the Company’s landlord, BDG Kingsbridge L.L.C., predecessor-in-interest to Kingsbridge 2005, LLC (the “Prime Landlord”), as a condition to providing its consent to the sublease contemplated by the Amended and Restated Sublease Agreement (the “Sublease”). On November 14, 2013, the Company received the Prime Landlord’s consent to the Sublease. Accordingly, the term of the Sublease commenced on November 14, 2013 and will expire on July 30, 2021, which is one day prior to the expiration of the lease under which the Company currently leases its premises from the Prime Landlord. Pursuant to the Amended and Restated Sublease Agreement, the Company sublet to Axcellerate a portion of the Company’s premises consisting of approximately 30,000 rentable square feet of the building located at 20 Kingsbridge Road, Piscataway, New Jersey and a share of related parking areas (the “Sublease”). The Company’s premises located at 20 Kingsbridge Road, Piscataway, New Jersey are currently leased by the Company pursuant to an agreement of lease dated as of April 1, 1995, as amended by that certain First Amendment to Lease dated as of November 13, 2001 (the “Prime Lease”), with the Prime Landlord. The rights of Axcellerate under the Sublease will be subject to the terms of the Prime Lease. The monthly fixed rent payable by Axcellerate under the Sublease will be as follows on a straight-line basis: (i) in year one, $ 10,417, (ii) in year two, $ 15,625, (iii) in year three, $ 20,833, (iv) in year four, $ 26,042 and (v) in each of years five through eight, $ 35,000. The Sublease also provides for Axcellerate to pay additional rent to cover its applicable share of real estate taxes, operating expenses, sewer and gas usage, water usage, electricity usage and certain other charges incurred by Axcellerate.

	The future minimum lease payment, for the Company’s non-cancelable operating lease as of December 31, 2013 is as follows (in thousands):

	Year ending December 31,		Operating
	Year ending December 31,		Lease
	2015		$	703
	2016			703
	2017			742
	2018			774
	Thereafter			1,998
	Total minimum lease payments		$	4,920

	Minimum payments indicated above have not been reduced by future minimum rentals to be received under the noncancelable sublease of approximately, as follows (in thousands):

	Year ending December 31,		Operating
	Year ending December 31,		Sublease

	2015		$	193
	2016			258
	2017			356
	2018			420
	Thereafter			1,085
	Total minimum sublease payments		$	2,312

Retirement_Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	-20	Retirement Plans

	The Company’s defined contribution 401(k) pension plan was terminated on June 30, 2013. The Company matched 50 percent of the employee’s contribution of up to 6 percent of compensation, as defined. The total Company contributions for the years ended December 31, 2014 and 2013 were $0 and $56,000, respectively.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation

	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.

Use of Estimates, Policy [Policy Text Block]	Use of Estimates

	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U. S. requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the carrying value of property and equipment, valuation of investments, legal and contractual contingencies, research and development expenses, stock-based compensation, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments and Fair Value

	The carrying values of cash, cash equivalents, marketable securities and other current assets, accounts payable and accrued expenses in the Company’s consolidated balance sheets approximated their fair values at December 31, 2014 and 2013 due to their short-term nature. As of December 31, 2014, the Company held no cash equivalents or marketable securities.

Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents

	The Company considers all highly liquid debt instruments purchased with original maturities of three months or less to be cash equivalents. As of December 31, 2014 and 2013, the Company held no cash equivalents.

Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition

	Royalty revenues from the Company’s agreements with third parties is recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee, which is typically during the quarter following the quarter in which the sales occurred. The Company does not participate in the selling or marketing of products for which it receives royalties. No provision for uncollectible accounts is established upon recognition of revenues.

	Contingent payments due under the asset purchase agreement for the sale of the Company’s former specialty pharmaceutical business are recognized as income when the milestone has been achieved and collection is assured. Such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process.

	The Company has discontinued all research and development activities.

Income Tax, Policy [Policy Text Block]	Income Taxes

	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.

	Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense.

Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Risk

	At December 31, 2014 and 2013, the Company had invested none of its cash in financial instruments, nor does it anticipate holding such instruments in the future. In prior periods, holdings of financial instruments, were comprised, principally, of money market funds and debt securities.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Plans

	The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned.

	The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at date of grant or modification and vesting, including the likelihood of achieving performance goals. Furthermore, the application of the Black-Scholes valuation model employs weighted average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk free interest rate, and dividends, if any to determine fair value. Expected volatility is based on historical volatility of the Company’s common stock; the expected term until exercise represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.

Cash Flow In formation Policy [Policy Text Block]	Cash Flow Information

	Cash payments for interest on the Company’s 4% convertible notes were approximately $2.3 million for the year ended December 31, 2013. There were approximately $55,500 and $186,000 (for which a refund request was submitted) of income tax payments made for the years ended December 31, 2014 and 2013, respectively.

Accrued_Expenses_and_Other_Tab

Accrued Expenses and Other (Tables)	12 Months Ended
Accrued Expenses and Other (Tables)	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities consist of the following as of December 31, 2014 and 2013 (in thousands):

		December 31,		December 31,
		2014		2013
	Compensation	$	5	$	85
	Severance benefits		-		332
	Professional and consulting fees		88		150
	Legal		-		160
	Rent		171		239
	Other		194		249
		$	458	$	1,215

Restructurings_Tables

Restructurings (Tables)	12 Months Ended
Restructurings (Tables)	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the changes in the Company’s accrued restructuring liabilities for the year ended December 31, 2014 and 2013 (in thousands):

		2014		2013

	Balance, beginning of year	$	905	$	777
	Payments made		-555		-4,648
	Adjustments		-82		-167
	Restructuring accruals		-		4,943

	Balance, end of year	$	268	$	905

Stock_Options_Tables

Stock Options (Tables)	12 Months Ended
Stock Options (Tables)	Dec. 31, 2014
Stock Options Abstract [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of the activity in the Company’s outstanding Stock Option Plans, which include the 2011 Stock Option and Incentive Plan, the 2001 Incentive Stock Plan, and the 1987 Non-Qualified Stock Option Plan (options in thousands):

				Weighted			Weighted
				Average			Average
				Exercise			Remaining		Aggregate
				Price Per			Contractual		Intrinsic
		Options		Option			Term (years)		Value ($000)

	Outstanding at January 1, 2014		2,125	$	6.9
	Granted at exercise prices which equaled the fair value on the date of grant		-	$	-
	Exercised		-	$	-

				$	-
	Expired and Forfeited		-1,606	$	7.64

	Outstanding at December 31, 2014		519	$	4.08			2.53	$	-

	Vested and expected to vest at December 31, 2014		519	$	4.08			2.53	$	-

	Exercisable at December 31, 2014		470	$	4.51			2.26	$	-

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The breakdown of stock-based compensation expense related to stock options by major line caption in the statements of income is shown below (in thousands):

		Year Ended December 31,
		2014		2013
	Research and development	$	-	$	5
	General and administrative		-		75
		$	-	$	80

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The risk-free interest rate is based on U.S. Treasury yields for securities in effect at the time of grant with terms approximating the expected term until exercise of the option. No dividend payments were factored into the valuations. Forfeiture rates, used for determining the amount of compensation cost to be recognized over the service period, are estimated based on stratified historical data.

		Year Ended December 31,
		2013
	Expected volatility					34.3	%
	Expected term (in years)					4	%
	Risk-free interest rate					0.8	%

Restricted_Stock_Awards_and_Re1

Restricted Stock Awards and Restricted Stock Units (Nonvested Shares) (Tables)	12 Months Ended
	Dec. 31, 2014
Restricted Stock Awards And Restricted Stock Units [Abstract]
Schedule of Nonvested Share Activity [Table Text Block]	A summary of nonvested shares as of December 31, 2014 and changes during the year ended December 31, 2014 is provided below (shares in thousands):

				Weighted
				Average
		Number of		Grant Date
		Nonvested		Fair Value
		Shares		Per Share
	Nonvested at January 1, 2014		166	$	8.13
	Granted		-	$	-
	Vested		-121	$	8.77
	Forfeited		-	$	-
	Adjustment pursuant to special dividend		-	$	-
	Nonvested at December 31, 2014		45	$	6.33

Schedule Of Restricted Stock Based Compensation Expense [Table Text Block]	The breakdown of stock-based compensation expense related to nonvested shares by major line caption in the statements of income is shown below (in thousands):

		Year Ended December 31,
		2014		2013

	Research and development	$	-	$	210

	General and administrative		-		-491

		$	-	$	-281

Employee_Stock_Purchase_Plan_T

Employee Stock Purchase Plan (Tables)	12 Months Ended
Employee Stock Purchase Plan (Tables)	Dec. 31, 2014
Employee Stock Purchase Plan [Abstract]
Schedule of Assumptions Used [Table Text Block]	The initial assumptions used in the valuation for each offering period, April 1 and October 1, are reflected in the following table (no dividends were assumed):

		2014				2013
		October		April		October		April

	Expected volatility		N/A		N/A		N/A		26.34	%
	Expected term (in years)		N/A		N/A		N/A		0.5
	Risk-free interest rate		N/A		N/A		N/A		0.15	%

Schedule Of Share Based Compensation Expense [Table Text Block]	The categorization of stock-based compensation expense by major line caption in the statement of operations is shown below (in thousands).

		Year Ended December 31,
		2014		2013
	Research and development	$	-	$	-3
	General and administrative		-		-1
		$	-	$	-4

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the income tax provision (benefit) are summarized as follows (in thousands):

		Year Ended December 31,
		2014		2013
	Current:
	Federal	$	-	$	-30
	State and foreign		56		2
	Total current		56		-28
	Deferred: Federal and State		-		-

	Income tax provision (benefit)	$	56	$	-28

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The following table represents reconciliation between the reported income taxes and the income taxes that would be computed by applying the federal statutory rate ( 35 %) to income from continuing operations before taxes (in thousands):

		Year Ended December 31,
		2014		2013
	Income tax expense computed at federal statutory rate	$	10,097	$	6,313
	Nondeductible expenses		-		183
	Add (deduct) effect of:
	Tax on earnings of foreign subsidiary		56		-
	State income taxes, net of federal tax		-		2

	Increase (decrease) in beginning of period valuation allowance		-10,097		-6,526

	Income tax provision (benefit)	$	56	$	-28

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2014 and 2013, the tax effects of temporary differences that give rise to the deferred tax assets and deferred tax liabilities are as follows (in thousands):

		December 31,		December 31,
		2014		2013
	Deferred tax assets:
	Federal and state net operating loss carryforward	$	45,221	$	56,198
	Research and development credits carryforward		19,911		25,379
	Basis difference in fixed Assets		2,915		3,526
	Capital loss carryforwards		3,647		3,663
	Share-based compensation		2,518		2,518
	Federal alternative minimum tax credits		1,530		1,530
	Writedown of carrying value of investment		-		-
	Accrued compensation		43		84
	Other		1,109		1,537
	Total gross deferred tax assets		76,894		94,435
	Less valuation allowance		-76,894		94,935
	Net deferred tax assets	$	-	$	-

Leases_Tables

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2014
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	The future minimum lease payment, for the Company’s non-cancelable operating lease as of December 31, 2013 is as follows (in thousands):

	Year ending December 31,	Operating
	Year ending December 31,	Lease
	2015	$	703
	2016		703
	2017		742
	2018		774
	Thereafter		1,998
	Total minimum lease payments	$	4,920

Schedule Of Future Minimum Rental Payments For Operating Subleases Table [Table Text Block]	Minimum payments indicated above have not been reduced by future minimum rentals to be received under the noncancelable sublease of approximately, as follows (in thousands):

	Year ending December 31,	Operating
	Year ending December 31,	Sublease

	2015	$	193
	2016		258
	2017		356
	2018		420
	Thereafter		1,085
	Total minimum sublease payments	$	2,312

Description_of_Business_Detail

Description of Business (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
	sqft	sqft	Dec. 31, 2013
Description of Business [Line Items]
Area of Land	30,000	30,000
Monthly Fixed Rent Receivable On Sublease, Year One	$10,417	$10,417
Monthly Fixed Rent Receivable On Sublease, Year Two	15,625	15,625
Monthly Fixed Rent Receivable On Sublease, Year Three	20,833	20,833
Monthly Fixed Rent Receivable On Sublease, Year Four	26,042	26,042
Monthly Fixed Rent Receivable On Sublease In Each Of Year Five To Eight	$35,000	$35,000
Royalty Revenues From Sales Percentage		79.00%	87.00%
Sub Lease commencement Date	14-Nov-13	14-Nov-13
Sublease Expiration Date	30-Jul-21	30-Jul-21

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Line Items]
Income Taxes Paid	$55,500	$186,000
Convertible Debt [Member]
Accounting Policies [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Interest Paid		$2,300,000

Marketable_Securities_Details_

Marketable Securities (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Schedule of Trading Securities and Other Trading Assets [Line Items]
Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds	$0.30

Accrued_Expenses_and_Other_Det

Accrued Expenses and Other (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses And Others [Line Items]
Compensation	$5	$85
Severance benefits	0	332
Professional and consulting fees	88	150
Legal	0	160
Rent	171	239
Other	194	249
Accrued expenses and other	$458	$1,215

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	12 Months Ended	48 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 21, 2010
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount				$200
Right Expiry Date	16-May-12
Stock Repurchased And Retired During Period Average Price Paid Per Share		$9.48
Preferred Stock, Shares Authorized	3,000,000	3,000,000	3,000,000
Stock Repurchased and Retired During Period, Shares		16,174,578
Stock Repurchased and Retired During Period, Value		$153.40
Non-Qualified and Incentive Stock Plans [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	7,097,697	7,097,697
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	600,000	600,000

Miscellaneous_Income_Details_T

Miscellaneous Income (Details Textual) (Axcellerate [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Axcellerate [Member]
Miscellaneous Income [Line Items]
Operating Leases, Income Statement, Sublease Revenue	$135,000	$87,000

Cash_Dividend_Details_Textual

Cash Dividend (Details Textual) (USD $)	0 Months Ended		1 Months Ended
Cash Dividend (Details Textual) (USD $)	Dec. 05, 2014	Dec. 05, 2013	Apr. 23, 2013
Schedule Of Cash Dividend [Line Items]
Common Stock, Dividends, Per Share, Declared	$0.10	$0.45	$1.60

Income_Per_Common_Share_Detail

Income Per Common Share (Details Textual)	12 Months Ended
Income Per Common Share (Details Textual)	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Common Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	22,000

Restructurings_Details

Restructurings (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]
Balance, beginning of year	$905	$777
Stock Issued During Period, Value, Share-based Compensation, Gross	-555	-4,648
Adjustments	-82	-167
Restructuring accruals	0	4,943
Balance, end of year	$268	$905

Restructurings_Details_Textual

Restructurings (Details Textual) (USD $)	12 Months Ended
Restructurings (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]
Separation Cost	$0	$4,800,000
Benefits Provided To Existing Employees On Accrual Utilization	$4,000,000	$32,000

Stock_Options_Details

Stock Options (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Stock Option [Line Items]
Options Outstanding at January 1, 2014	2,125
Options Granted at exercise prices which equaled the fair value on the date of grant	0
Options Exercised	0
Expired and Forfeited	-1,606
Options Outstanding at December 31, 2014	519
Options Vested and expected to vest at December 31, 2014	519
Options Exercisable at December 31, 2014	470
Outstanding at January 1, 2014, Weighted Average Exercise Price per Option	$6.90
Granted, Weighted Average Exercise Price per Option	$0
Exercised, Weighted Average Exercise Price per Option	$0
Forfeited And Expired, Weighted Average Exercise Price per Option	$7.64
Outstanding at December 31, 2014, Weighted Average Exercise Price per Option	$4.08
Vested and expected to vest at December 31, 2014, Weighted Average Exercise Price per Option	$4.08
Exercisable at December 31, 2014, Weighted Average Exercise Price per Option	$4.51
Outstanding at December 31, 2014, Weighted Average Remaining Contractual Term (years)	2 years 6 months 11 days
Vested and expected to vest at December 31, 2014, Weighted Average Remaining Contractual Term (years)	2 years 6 months 11 days
Exercisable at December 31, 2014, Weighted Average Remaining Contractual Term (years)	2 years 3 months 4 days
Outstanding at December 31, 2014, Aggregate Intrinsic Value	$0
Vested and expected to vest at December 31, 2014, Aggregate Intrinsic Value	0
Exercisable at December 31, 2014, Aggregate Intrinsic Value	$0

Stock_Options_Details_1

Stock Options (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Stock Option [Line Items]
Allocated Share-based Compensation Expense	$0	$4
Equity Option [Member]
Stock Option [Line Items]
Allocated Share-based Compensation Expense	0	80
Equity Option [Member] \| Research and Development Expense [Member]
Stock Option [Line Items]
Allocated Share-based Compensation Expense	0	5
Equity Option [Member] \| General and Administrative Expense [Member]
Stock Option [Line Items]
Allocated Share-based Compensation Expense	$0	$75

Stock_Options_Details_2

Stock Options (Details 2 )	1 Months Ended				12 Months Ended
Stock Options (Details 2 )	Oct. 30, 2014	Apr. 30, 2014	Oct. 30, 2013	Apr. 30, 2013	Dec. 31, 2013
Stock Option [Line Items]
Expected volatility				26.34%	34.30%
Expected term (in years)				6 months	4 years
Risk-free interest rate				0.15%	0.80%

Stock_Options_Details_Textual

Stock Options (Details Textual) (USD $)	0 Months Ended		3 Months Ended		12 Months Ended		3 Months Ended		1 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Dec. 05, 2014	Dec. 05, 2013	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2011	Mar. 31, 2013	Mar. 31, 2011
Allocated Share-based Compensation Expense					$0	$4,000
Stock Issued During Period, Value, Share-based Compensation, Gross					-30,000	-484,000
Common Stock, Dividends, Per Share, Cash Paid	$0.10	$0.45	$0.45	$1.60	$0	$2.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$0	$1.24
Stock or Unit Option Plan Expense					0	100,000
Outside Director Compensation Plan 2011 [Member]
Stock Issued During Period, Value, Share-based Compensation, Gross							25,000
Outside Director Compensation Plan 2011 [Member] \| New Director [Member]
Stock Issued During Period, Value, Share-based Compensation, Gross							25,000
2013 Plan Annual Option Grant {Member]
Stock Issued During Period, Value, Share-based Compensation, Gross								25,000
2013 Plan Annual Option Grant {Member] \| New Director [Member]
Stock Issued During Period, Value, Share-based Compensation, Gross								25,000
2013 Plan Annual Restricted Stock Grant [Member]
Stock Issued During Period, Value, Share-based Compensation, Gross								50,000
Stock Issued During Period, Value, Stock Dividend								50,000
2013 Plan Annual Restricted Stock Grant [Member] \| New Director [Member]
Stock Issued During Period, Value, Share-based Compensation, Gross								50,000
Stock Issued During Period, Value, Stock Dividend								50,000
2013 Plan Annual Option And Restricted Stock Grant [Member] \| Vice-Chairperson [Member]
Non Employee Chairperson Grants Number Of Times Of Value Of Grants								1.75
2013 Outside Director Compensation Plan [Member]
Annual Cash Retainer To Non Employee Directors								30,000
2013 Outside Director Compensation Plan [Member] \| Chairperson Of Finance And Audit Committee [Member]
Additional Annual Cash Retainer To Non Employee Directors For Services								18,000
2013 Outside Director Compensation Plan [Member] \| Chairperson Of Other Committee [Member]
Additional Annual Cash Retainer To Non Employee Directors For Services								8,000
2013 Outside Director Compensation Plan [Member] \| Members of Audit and Finance Committee [Member]
Additional Annual Cash Retainer To Non Employee Directors For Services								8,000
2013 Outside Director Compensation Plan [Member] \| Members Of Other Committee [Member]
Additional Annual Cash Retainer To Non Employee Directors For Services								4,000
Amended and Restated 2013 Outside Director Compensation Plan [Member]
Annual Cash Retainer To Non Employee Directors				30,000
Amended and Restated 2013 Outside Director Compensation Plan [Member] \| Chairperson Of Other Committee [Member]
Additional Annual Cash Retainer To Non Employee Directors For Services				10,000
Amended and Restated 2013 Outside Director Compensation Plan [Member] \| Members Of Committee [Member]
Additional Annual Cash Retainer To Non Employee Directors For Services				5,000
Outside Director Compensations Plan 2007 [Member]
Stock Issued During Period, Value, Share-based Compensation, Gross									75,000
Outside Director Compensations Plan 2007 [Member] \| New Director [Member]
Stock Issued During Period, Value, Share-based Compensation, Gross									$75,000
2011 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					5
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					4.4

Restricted_Stock_Awards_and_Re2

Restricted Stock Awards and Restricted Stock Units (Nonvested Shares) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Nonvested at January 1, 2013, Number of Nonvested Shares	166
Granted, Number of Nonvested Shares	0
Vested, Number of Nonvested Shares	-121
Forfeited, Number of Nonvested Shares	0
Adjustment pursuant to special dividend, Number of Nonvested Shares	0
Nonvested at December 31, 2014, Number of Nonvested Shares	45
Nonvested at January 1, 2014, Weighted Average Grant Date Fair Value Per Share	$8.13
Granted, Weighted Average Grant Date Fair Value Per Share	$0
Vested, Weighted Average Grant Date Fair Value Per Share	$8.77
Forfeited, Weighted Average Grant Date Fair Value Per Share	$0
Adjustment pursuant to special dividend, Weighted Average Grant Date Fair Value Per Share	$0
Nonvested at December 31, 2014, Weighted Average Grant Date Fair Value Per Share	$6.33

Restricted_Stock_Awards_and_Re3

Restricted Stock Awards and Restricted Stock Units (Nonvested Shares) (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Allocated Share-based Compensation Expense	$0	$4
Restricted Stock Units (RSUs) [Member]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Allocated Share-based Compensation Expense	0	-281
Restricted Stock Units (RSUs) [Member] \| Research and Development Expense [Member]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Allocated Share-based Compensation Expense	0	210
Restricted Stock Units (RSUs) [Member] \| General and Administrative Expense [Member]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Allocated Share-based Compensation Expense	$0	($491)

Restricted_Stock_Awards_and_Re4

Restricted Stock Awards and Restricted Stock Units (Nonvested Shares) (Details Textual) (USD $)	0 Months Ended		3 Months Ended		12 Months Ended		1 Months Ended
	Dec. 05, 2014	Dec. 05, 2013	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2011
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Common Stock, Par or Stated Value Per Share			$0.01		$0.01	$0.01
Common Stock, Dividends, Per Share, Cash Paid	$0.10	$0.45	$0.45	$1.60	$0	$2.05
Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation					$30,000	$500,000
Allocated Share-based Compensation Expense					0	4,000
Employee Service Share Based Compensation Tax Payments					30,000	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value					200,000
Nonvested Shares Award [Member]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Allocated Share-based Compensation Expense					10,000	300,000
Outside Director Compensation Plan 2007 [Member]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures							75,000
Outside Director Compensation Plan 2007 [Member] \| New Director [Member]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures					75,000
Outside Director Compensation Plan 2011 [Member] \| New Director [Member]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures					$100,000		$75,000

Employee_Stock_Purchase_Plan_D

Employee Stock Purchase Plan (Details)	1 Months Ended				12 Months Ended
Employee Stock Purchase Plan (Details)	Oct. 30, 2014	Apr. 30, 2014	Oct. 30, 2013	Apr. 30, 2013	Dec. 31, 2013
Employee Stock Purchase Plan [Line Items]
Expected volatility				26.34%	34.30%
Expected term (in years)				6 months	4 years
Risk-free interest rate				0.15%	0.80%

Employee_Stock_Purchase_Plan_D1

Employee Stock Purchase Plan (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Purchase Plan [Line Items]
Allocated Share-based Compensation Expense	$0	$4
Employee Stock [Member]
Employee Stock Purchase Plan [Line Items]
Allocated Share-based Compensation Expense	0	-4
Employee Stock [Member] \| General and Administrative Expense [Member]
Employee Stock Purchase Plan [Line Items]
Allocated Share-based Compensation Expense	0	-1
Employee Stock [Member] \| Research and Development Expense [Member]
Employee Stock Purchase Plan [Line Items]
Allocated Share-based Compensation Expense	$0	($3)

Employee_Stock_Purchase_Plan_D2

Employee Stock Purchase Plan (Details Textual) (USD $)	12 Months Ended
Employee Stock Purchase Plan (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Purchase Plan [Line Items]
Allocated Share-based Compensation Expense	$0	$4,000
Employee Stock Purchase Plan Description	The 2007 Employee Stock Purchase Plan (ESPP) permits eligible employees to purchase common stock through payroll deductions which may not exceed 15 percent of the employee’s compensation, as defined, at a price equal to 85 percent of the fair market value of the shares at the beginning of the offering period (grant date) or at the end of the offering period (purchase date), whichever is lower. All benefit-eligible employees of the Company may participate in the ESPP other than those who own shares or hold options or nonvested shares representing a combined 5 percent or more of the voting power of the Company’s outstanding stock. The ESPP was terminated on April 1, 2013.
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	50.00%
Employee Stock Purchase Plan Termination Income	4,000
Payment To Employee Stock Purchase Plan Termination	14,000
Employee Stock Purchase Plan 2007 [Member]
Employee Stock Purchase Plan [Line Items]
Allocated Share-based Compensation Expense	0	0
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	15.00%
Description Of Price Of Employee Share Based Compensation	price equal to 85 percent of the fair market value of the shares at the beginning of the offering period (grant date) or at the end of the offering period (purchase date), whichever is lower
Employee Stock Purchase Plan Participation Description	All benefit-eligible employees of the Company may participate in the ESPP other than those who own shares or hold options or nonvested shares representing a combined 5 percent or more of the voting power of the Companys outstanding stock. The ESPP was terminated on April 1, 2013.
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Purchased Individually Per Day	2,500
Maximum Purchase Available Under Plan	25,000
Maximum Purchase Available After Discount Under Plan	$21,250
Percentage Discount On Maximum Purchase Available Under Plan	15.00%

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$0	($30)
State and foreign	56	2
Total current	56	-28
Deferred: Federal and State	0	0
Income tax provision (benefit)	$56	($28)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule of Income Taxes [Line Items]
Income tax expense computed at federal statutory rate	$10,097	$6,313
Nondeductible expenses	0	183
Add (deduct) effect of:
Tax on earnings of foreign subsidiary	56	0
State income taxes, net of federal tax	0	2
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	-10,097	-6,526
Income tax provision (benefit)	$56	($28)

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Federal and state net operating loss carryforward	$45,221	$56,198
Research and development credits carryforward	19,911	25,379
Basis difference in fixed Assets	2,915	3,526
Capital loss carryforwards	3,647	3,663
Share-based compensation	2,518	2,518
Federal alternative minimum tax credits	1,530	1,530
Writedown of carrying value of investment	0	0
Accrued compensation	43	84
Other	1,109	1,537
Total gross deferred tax assets	76,894	94,435
Less valuation allowance	-76,894	94,935
Net deferred tax assets	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
Income Taxes (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	35.00%
Deferred Tax Assets, Net, Current	$76,900,000	$94,400,000
Deferred Tax Assets, Valuation Allowance	-76,894,000	94,935,000
Operating Loss Carryforwards, Limitations on Use	At December 31, 2014, the Company had federal net operating loss carryforwards of approximately $117.4 million that expire in the years 2020 through 2031 and New Jersey state net operating loss carryforwards of approximately $45.7 million that expire in the years 2029 through 2031. Moreover, the Company has federal and New Jersey capital loss carryforwards of approximately $8.9 million that expire in 2016 through 2019. The Company also has federal research and development tax credit carryforwards of approximately $16.6 million for tax reporting purposes that expire in the years 2017 through 2031. In addition, the Company has $3.3 million of state research and development tax credit carryforwards that expire in the years 2015 through 2026.
Income Tax Examination, Description	the Company concluded an examination by the U.S. Internal Revenue Service, in connection with the tax years 2010 through 2011. The result of such examination was the reduction of federal net operating loss carryforwards aggregating approximately $1.8 million. State income tax returns for the states of New Jersey and Indiana are generally subject to examination for a period of 3-4 years after filing of the respective returns. Income tax returns for Canada are generally subject to examination for a period of 3-5 years after filing of the respective return.
Federal [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$1,800,000

Significant_Agreements_Details

Significant Agreements (Details Textual) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended		36 Months Ended	3 Months Ended	1 Months Ended
Significant Agreements (Details Textual) (USD $)	Jul. 16, 2014	Sep. 30, 2007	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
Significant Agreements Line item [Line Items]
Milestone Payment			$5,000,000
Sub-Lease, Description					34,000,000
Royalties Pursuant To Provision In Sales Agreement			500,000
Percentage Of Royalty Payable Sold Under Merck Agreement		25.00%
Uncertain Milestone Payment			17,000,000
Revenue Recognition, Milestone Method, Revenue Recognized				27,000,000
Milestone Agreement Description	Belrose provided written notice to Hisun asserting multiple breaches by Hisun of the Collaboration Agreement including failure to pay $450,000 of milestone payments. Belrose provided Hisun up to 60 days to cure the breaches.
Selling, General and Administrative Expenses [Member]
Significant Agreements Line item [Line Items]
Selling General And Administrative Expense						300,435
Sigma Tau Group [Member]
Significant Agreements Line item [Line Items]
Percentage Of Royalty On Sale Due To Enzone				5 to 10 percent
European Medicines Agency [Member]
Significant Agreements Line item [Line Items]
Due From Related Party Contingent Consideration				5,000,000
Fda Ss Oncaspar [Member]
Significant Agreements Line item [Line Items]
Due From Related Party Contingent Consideration				5,000,000
FDA SC Oncaspar [Member]
Significant Agreements Line item [Line Items]
Due From Related Party Contingent Consideration				7,000,000
Non Accelerated Ema Sc Oncaspar [Member]
Significant Agreements Line item [Line Items]
Due From Related Party Contingent Consideration				10,000,000
Zhejiang Hisun Pharmaceutical Co., Ltd. Hisun [Member]
Significant Agreements Line item [Line Items]
Notes Receivable Gross							550,000
Belrose [Member]
Significant Agreements Line item [Line Items]
Notes Payable							$249,565

Leases_Details

Leases (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Leases [Line Items]
2015	$703
2016	703
2017	742
2018	774
Thereafter	1,998
Total minimum lease payments	$4,920

Leases_Details_1

Leases (Details 1) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Leases [Line Items]
2015	$193
2016	258
2017	356
2018	420
Thereafter	1,085
Total minimum sublease payments	$2,312

Leases_Details_Textual

Leases (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2014
	sqft	sqft
Leases [Line Items]
Area of Land	30,000	30,000
Monthly Fixed Rent Receivable On Sublease, Year One	$10,417	$10,417
Monthly Fixed Rent Receivable On Sublease, Year Two	15,625	15,625
Monthly Fixed Rent Receivable On Sublease, Year Three	20,833	20,833
Monthly Fixed Rent Receivable On Sublease, Year Four	26,042	26,042
Monthly Fixed Rent Receivable On Sublease In Each Of Year Five To Eight	$35,000	$35,000
Sub Lease commencement Date	14-Nov-13	14-Nov-13
Sublease Expiration Date	30-Jul-21	30-Jul-21

Retirement_Plans_Details_Textu

Retirement Plans (Details Textual) (USD $)	12 Months Ended
Retirement Plans (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Retirement Plans [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$0	$56,000
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	50.00%